Thomas Jefferson University

Jefferson Digital Commons
Division of Cardiology Faculty Papers

Division of Cardiology

12-1-2020

Outcomes of Mechanical Circulatory Support for Giant Cell
Myocarditis: A Systematic Review
Preeyal M. Patel
Thomas Jefferson University

Abhiraj Saxena
Thomas Jefferson University

Chelsey T. Wood, MFA
Thomas Jefferson University

Thomas J. O'Malley
Thomas Jefferson University
Follow this and additional works at: https://jdc.jefferson.edu/cardiologyfp

Elizabeth Maynes

Part of
the Cardiology
Commons
Thomas
Jefferson
University

Let us know how access to this document benefits you
See next page for additional authors

Recommended Citation
Patel, Preeyal M.; Saxena, Abhiraj; Wood, MFA, Chelsey T.; O'Malley, Thomas J.; Maynes,
Elizabeth; Entwistle, John W..C.; Massey, H. Todd; Pirlamarla, Preethi R; Alvarez, René J; Cooper,
Leslie T; Rame, J. Eduardo; and Tchantchaleishvili, Vakhtang, "Outcomes of Mechanical
Circulatory Support for Giant Cell Myocarditis: A Systematic Review" (2020). Division of
Cardiology Faculty Papers. Paper 88.
https://jdc.jefferson.edu/cardiologyfp/88
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Division of Cardiology Faculty Papers by an authorized administrator of the Jefferson
Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors
Preeyal M. Patel; Abhiraj Saxena; Chelsey T. Wood, MFA; Thomas J. O'Malley; Elizabeth Maynes; John
W..C. Entwistle; H. Todd Massey; Preethi R Pirlamarla; René J Alvarez; Leslie T Cooper; J. Eduardo Rame;
and Vakhtang Tchantchaleishvili

This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/cardiologyfp/88

Journal of

Clinical Medicine
Article

Outcomes of Mechanical Circulatory Support for
Giant Cell Myocarditis: A Systematic Review
Preeyal M. Patel 1 , Abhiraj Saxena 1 , Chelsey T. Wood 1 , Thomas J. O’Malley 2 ,
Elizabeth J. Maynes 2 , John W. C. Entwistle 2 , H. Todd Massey 2 , Preethi R. Pirlamarla 3 ,
René J. Alvarez 3 , Leslie T. Cooper 4 , J. Eduardo Rame 2 and Vakhtang Tchantchaleishvili 2, *
1
2

3
4

*

Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA;
preeyalp@gmail.com (P.M.P.); a.s.abhiraj.saxena@gmail.com (A.S.); chelseytylerwood@gmail.com (C.T.W.)
Division of Cardiac Surgery, Department of Surgery, Thomas Jefferson University, Philadelphia,
PA 19107, USA; tomalley89@gmail.com (T.J.O.); elizabethjanemd@gmail.com (E.J.M.);
john.entwistle@jefferson.edu (J.W.C.E.); howard.massey@jefferson.edu (H.T.M.);
eduardo.rame@jefferson.edu (J.E.R.)
Division of Cardiology, Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA;
preethi.pirlamarla@jefferson.edu (P.R.P.); rene.alvarez@jefferson.edu (R.J.A.)
Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL 32224, USA; cooper.leslie@mayo.edu
Correspondence: vakhtang.tchantchaleishvili@jefferson.edu; Tel.: +1-215-955-6996; Fax: +1-215-955-6010

Received: 20 October 2020; Accepted: 23 November 2020; Published: 1 December 2020




Abstract: Treatment of giant cell myocarditis (GCM) can require bridging to orthotopic heart
transplantation (OHT) or recovery with mechanical circulatory support (MCS). Since the roles of MCS
and immunotherapy are not well-defined in GCM, we sought to analyze outcomes of patients with
GCM who required MCS. A systematic search was performed in June 2019 to identify all studies of
biopsy-proven GCM requiring MCS after 2009. We identified 27 studies with 43 patients. Patient-level
data were extracted for analysis. Median patient age was 45 (interquartile range (IQR): 32–57) years.
42.1% (16/38) were female. 34.9% (15/43) presented in acute heart failure. 20.9% (9/43) presented in
cardiogenic shock. Biventricular (BiVAD) MCS was required in 76.7% (33/43) of cases. Of the 62.8%
(27/43) of patients who received immunotherapy, 81.5% (22/27) used steroids combined with at least
one other immunosuppressant. Cyclosporine was the most common non-steroidal agent, used in
40.7% (11/27) of regimens. Immunosuppression was initiated before MCS in 59.3% (16/27) of cases,
after MCS in 29.6% (8/27), and not specified in 11.1% (3/27). Immunosuppression started prior to MCS
was associated with significantly better survival than MCS alone (p = 0.006); 60.5% (26/43) of patients
received bridge-to-transplant MCS; 39.5% (17/43) received bridge-to-recovery MCS; 58.5% (24/41)
underwent OHT a median of 104 (58–255) days from diagnosis. GCM recurrence after OHT was
reported in 8.3% (2/24) of transplanted cases. BiVAD predominates in mechanically supported
patients with GCM. Survival and bridge to recovery appear better in patients on immunosuppression,
especially if initiated before MCS.
Keywords: myocarditis; mechanical circulatory support; immunosuppression; treatment; survival

1. Introduction
Giant cell myocarditis (GCM) is a rare autoimmune disorder characterized by diffuse myocardial
necrosis with multinucleated giant cells [1]. First described in 1905 by Saltikow [2], GCM is often
mistaken for other infiltrative cardiomyopathies [3] such as cardiac sarcoidosis and lymphocytic
myocarditis. Although these diseases may present similarly and share some histopathologic
features, GCM is most associated with a poor prognosis [4], resulting in severe heart failure and
ventricular arrhythmias.
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An electronic search was performed in June 2019 in the Cochrane, MEDLINE, Scopus,
Cumulative Index of Nursing and Allied Health Literature (CINAHL) databases to identify all
and Cumulative Index of Nursing and Allied Health Literature (CINAHL) databases to identify
reports of biopsy-proven giant cell myocarditis requiring mechanical circulatory support from 2009
all reports of biopsy-proven giant cell myocarditis requiring mechanical circulatory support from
through 2019. The keyword “giant cell myocarditis” was used to perform the search. Of the 2646
2009 through 2019. The keyword “giant cell myocarditis” was used to perform the search. Of the
articles identified, 27 articles, consisting of six case series and 21 case reports, with a total of 43 cases
2646 articles identified, 27 articles, consisting of six case series and 21 case reports, with a total of
met inclusion criteria. A Preferred Reporting Items for Systematic Reviews and Meta-Analysis
43 cases met inclusion criteria. A Preferred Reporting Items for Systematic Reviews and Meta-Analysis
(PRISMA) flow diagram outlining the literature search protocol is provided as Figure 1. No
(PRISMA) flow diagram outlining the literature search protocol is provided as Figure 1. No institutional
institutional review board approval was required for this study, given that all data were collected
review board approval was required for this study, given that all data were collected from previously
from previously published articles.
published articles.
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) diagram
outlining literature search strategy for systematic review.
outlining literature search strategy for systematic review.
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2.2. Inclusion Criteria
Only biopsy-proven cases of giant cell myocarditis were included in this study. All adults 18 years
or older with MCS, including CF-LVADs, biventricular assist devices (BiVAD), and total artificial
hearts (TAH), were included in the study. Due to limited available data, case series and case reports
were selected.
2.3. Data Extraction
Patient-level data were extracted and pooled for statistical analysis from the body, figures, and tables
of selected case series and case reports. In situations where data were not available, attempts were
made to contact corresponding authors, but no additional data were successfully retrieved.
2.4. Statistical Analysis
Baseline characteristics were reported as descriptive statistics, including medians and interquartile
ranges (IQR) for continuous variables and percentages for categorical variables. Patients were
dichotomized into those who received MCS (MCS alone) and those who received immunosuppression
in addition to MCS (MCS + IS). Individual patient survival and follow up data from each article were
combined for Kaplan–Meier survival analysis censored for death. Log-rank test was performed to
compare survival by timing of immunotherapy (IS pre-MCS, IS post-MCS, or MCS alone) and by
MCS modality (LVAD or BiVAD). Additionally, immunosuppression status and use of temporary
MCS before durable MCS as potential markers of patient acuity were examined using univariable and
multivariable Cox proportional hazard regression models. p-values less than 0.05 were considered
statistically significant. All analyses were performed with R software, version 3.5.1 (R Foundation for
Statistical Computing, Vienna, Austria).
2.5. Evaluation of Missing Data
The articles included in this systematic review did not all report the same variables. The discrepancy
required certain interpretations and adjustments to resolve the missing data. Denominators were
adjusted when calculating percentage values for missing categorical data. Routine variables such
as demographics and baseline characteristics were evaluated as missing at random, while variables
representing major adverse events were interpreted to not have occurred if not explicitly mentioned.
Given that the missing baseline characteristics were not necessary for survival analysis, we determined
that the missing data would not meaningfully impact our discussion of survival outcomes, the primary
focus of this paper. Therefore, no further intervention beyond denominator adjustment was performed.
3. Results
3.1. Baseline Characteristics
Median patient age was 45 (IQR: 32–57) years, and 42.1% (16/38) of patients were female;
20.0% (8/40) of patients had a history of autoimmune disease, including 7.5% (3/40) with Hashimoto’s
thyroiditis, 5.0% (2/40) with rheumatoid arthritis, 2.5% (1/40) with celiac disease, 2.5% (1/40) with
Grave’s disease, and 2.5% (1/40) with ulcerative colitis. No patients reported a history of thymoma or
other tumors. Baseline characteristics of patients included in the study are shown in Table 1.
Patients reported the onset of symptoms a median of 7 (7–10) days prior to presentation.
34.9% (15/43) of patients presented in acute heart failure, and 20.9% (9/43) presented in cardiogenic
shock. Arrhythmias were detected in 57.1% (24/42) of patients, with complete atrioventricular (AV)
block and ventricular tachycardia being the most common. Of note, patients who received MCS + IS
had a significantly higher left ventricular ejection fraction (LVEF) at presentation compared to patients
who received MCS alone (28% (20–30) vs. 17% (13–20), p = 0.03). The final diagnosis of GCM was
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made using endomyocardial biopsy in 72.1% (31/43) of cases, left ventricular apical core biopsy in
23.3% (10/43) of cases, and biopsy of the explanted heart in 2.3% (1/43) of cases.
Table 1. Baseline characteristics of patients with giant cell myocarditis (GCM) supported with
mechanical circulatory support (MCS) alone or in combination with immunosuppression.
Baseline Characteristics 1
Female
Age at diagnosis (years)
History of autoimmune disease
History of thymoma or other tumors
Clinical presentation
Acute heart failure
Shortness of breath
Cardiogenic shock
Presyncope
Chest pain
Cardiac arrest requiring CPR
ST segment elevation
Arrhythmia
Ventricular tachycardia
Complete AV block
Right bundle branch block
Atrial fibrillation
Time from symptoms to admission (days)
Elevated cardiac enzymes
LVEF at presentation (%)
Biopsy proven
Endomyocardial biopsy
Apical sample during LVAD implantation
Explanted heart
Time from symptoms to diagnosis (days)
Initial inotropic support

MCS Alone (n = 16)

MCS + IS (n = 27)

Total (n = 43)

p-Value

5/11 (45.5)
41.0 (30.0, 55.0)
1/16 (6.2)
0/16 (0.0)

11/27 (40.7)
49.0 (34.5, 58.5)
7/24 (29.2)
0/24 (0.0)

16/38 (42.1)
44.5 (32.2, 56.5)
8/40 (20.0)
0/40 (0.0)

1.00
0.25
0.17
1.00

5/16 (31.2)
6/16 (37.5)
3/16 (18.8)
3/16 (18.8)
2/16 (12.5)
0/16 (0.0)
1/16 (6.2)
11/15 (73.3)
5/15 (33.3)
3/15 (20.0)
2/15 (13.3)
0/15 (0.0)
7 (6, 7)
8/16 (50.0)
17.0 (12.5, 20.0)
16/16 (100.0)
9/16 (56.2)
6/16 (37.5)
1/43 (6.2)
16 (4,21)
11/14 (78.6)

10/27 (37.0)
4/27 (14.8)
6/27 (22.2)
3/27 (11.1)
2/27 (7.4)
1/27 (3.7)
4/27 (14.8)
13/27 (48.1)
7/25 (28.0)
4/25 (16.0)
0/22 (0.0)
1/25 (4.0)
8 (7, 11)
3/27 (11.1)
28.0 (20.0, 30.0)
27/27 (100.0)
22/27 (81.5)
4/27 (14.8)
0/43 (0.0)
21 (9,54)
13/25 (52.0)

15/43 (34.9)
10/43 (23.3)
9/43 (20.9)
6/43 (14.0)
4/43 (9.3)
1/43 (2.3)
5/43 (11.6)
24/42 (57.1)
12/40 (30.0)
7/40 (17.5)
2/37 (5.4)
1/40 (2.5)
7 (7, 10)
11/43 (25.6)
20.0 (15.0, 28.2)
43/43 (100.0)
31/43 (72.1)
10/43 (23.3)
1/43 (2.3)
18.5 (7,54)
24/39 (61.5)

0.96
0.18
1.00
0.81
0.99
1.00
0.72
0.21
1.00
1.00
0.31
1.00
0.20
0.13
0.03
0.09
0.15
0.18
0.79
0.51
0.20

1

All values are reported as n (%) or median (interquartile range (IQR)). Abbreviations—MCS: mechanical circulatory
support, IS: immunosuppression, CPR: cardiopulmonary resuscitation, AV: atrioventricular, LVEF: left ventricular
ejection fraction, LVAD: left ventricular assist device.

Patients in both groups were similarly supported with temporary MCS prior to LVAD implantation.
These temporary devices included veno-arterial extracorporeal membrane oxygenation (VA ECMO) in
25.0% (9/36) of cases, intra-aortic balloon pump (IABP) in 16.7% (6/36) of cases, and Impella in 7.0%
(3/43) of cases. Two patients (4.7%) were transitioned from temporary LVAD to durable LVAD support,
and five (11.6%) patients were transitioned from temporary LVAD to durable BiVAD support. In two
cases, a temporary right ventricular assist device (RVAD) was placed before transitioning to a BiVAD.
The majority of patients (76.7%, 33/43) required a BiVAD, and the remaining 23.3% (10/43)
of patients received an LVAD. Most patients were mechanically supported as bridge-to-transplant
(60.5%, 26/43), while the remainder were supported as bridge-to-recovery (39.5%, 17/43). Patients were
maintained on MCS for a median of 39 (15–137) days. There was no significant difference in MCS
characteristics between the MCS alone and MCS + IS subgroups. A detailed outline of the temporary
and durable types of MCS used are depicted in Table 2.
An immunosuppressive regimen was used in 62.8% (27/43) of cases. Immunosuppression was
initiated before MCS (IS pre-MCS) in 59.3% (16/27) of cases, after MCS (IS post-MCS) in 29.6% (8/27)
of cases, and not specified in 11.1% (3/27) of cases. Of the patients receiving MCS + IS, the vast
majority, 81.5% (22/27), received combined immunosuppression consisting of steroids in combination
with at least one other immunosuppressant. Cyclosporine was the most common, administered to
40.7% (11/27) of patients. Other immunosuppressants included in the regimens are listed in Table 3.
Among patients requiring maintenance immunosuppression to prevent recurrence, steroids were the
most common long-term therapy, used in 42.3% (11/26) of cases.
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Table 2. MCS characteristics in patients with GCM.
MCS Characteristics 1

MCS Only (n = 16)

MCS + IS (n = 27)

Total (n = 43)

p-Value

MCS as initial treatment
MCS after immunosuppression failed
Time from admission to MCS (days)
Intra-aortic balloon pump
Impella
VA ECMO
Temporary LVAD prior to durable LVAD
Temporary LVAD prior to durable BiVAD
Any LVAD
Bridge to transplant
Bridge to recovery
Time from admission to LVAD (days)
VAD support duration (days)
Durable LVAD
HeartMate II LVAD
Jarvik 2000 LVAD
Unspecified durable LVAD
Any biventricular support
Durable BiVAD
HeartWare BiVAD
Total artificial heart
Unspecified durable BiVAD
Durable LVAD + Temporary RVAD
HeartMate II LVAD + Centrimag RVAD
HeartMate II LVAD + Abiomed RVAD
Temporary Centrimag BiVAD
Unspecified BiVAD

16/16 (100.0)

16/19 (84.2)
3/19 (15.8)
8 (4, 17)
4/22 (18.2)
3/27 (11.1)
7/23 (30.4)
1/27 (3.7)
2/27 (7.4)
27/27 (100.0)
18/27 (66.7)
9/27 (33.3)
8 (4, 17)
48 (17, 137)
6/27 (22.2)
2/27 (7.4)
1/27 (3.7)
3/27 (11.1)
21/27 (77.8)
7/27 (25.9)
3/27 (11.1)
1/27 (3.7)
1/27 (3.7)
2/27 (7.4)
1/27 (3.7)
1/27 (3.7)
4/27 (14.8)
8/27 (29.6)

32/35 (91.4)
3/35 (8.6)
9 (4, 22)
6/36 (16.7)
3/43 (7.0)
9/36 (25.0)
2/43 (4.7)
5/43 (11.6)
43/43 (100.0)
26/43 (60.5)
17/43 (39.5)
9 (4, 22)
39 (15, 137)
10/43 (23.3)
5/43 (11.6)
2/43 (4.7)
3/43 (7.0)
33/43 (76.7)
11/43 (25.5)
4/43 (9.3)
1/43 (2.3)
4/43 (9.3)
3/43 (7.0)
2/43 (4.7)
1/43 (2.3)
8/43 (18.6)
11/43 (25.5)

0.73

14 (5, 39)
2/14 (14.3)
0/16 (0.0)
2/13 (15.4)
1/16 (6.2)
3/16 (18.8)
16/16 (100.0)
8/16 (50.0)
8/16 (50.0)
14 (5, 39)
20 (13, 98)
4/16 (25.0)
3/16 (18.8)
1/16 (6.2)
0/16 (0.0)
12/16 (75.0)
4/16 (25.0)
1/16 (6.2)
0/16 (0.0)
3/16 (18.8)
1/16 (6.2)
1/16 (6.2)
0/16 (0.0)
4/16 (25.0)
3/16 (18.8)

0.38
1.00
0.45
0.55
1.00
0.53
0.09
0.45
0.45
0.38
0.54
1.00
0.53
1.00
0.45
1.00
0.95
1.00
1.00
1.00
0.88
1.00
1.00
0.67
0.43

1

All values are reported as n (%) or median (IQR). Abbreviations—MCS: mechanical circulatory support, GCM: giant
cell myocarditis, IS: immunosuppression, VA ECMO: veno-arterial extracorporeal membrane oxygenation, LVAD: left
ventricular assist device, BiVAD: biventricular assist device, RVAD: right ventricular assist device.

Table 3. Characteristics of immunotherapy associated with short and long-term maintenance.
Characteristics of Immunotherapy 1
Initial (short-term) immunosuppression
Immunosuppressants per regimen
Immunosuppression as first-line treatment
Immunosuppression started after VAD
Steroid-free regimen
Steroids alone
Combined steroids + other immunosuppressant 2
Cyclosporine
Cyclophosphamide
IV immunoglobulin
Antithymocyte globulin
Mycophenolate mofetil
Azathioprine
Tacrolimus
Rituximab
Muromonab
Maintenance (long-term) immunosuppression
Maintenance immunosuppression 2
Steroids
Cyclosporine
Mycophenolate mofetil
Tacrolimus
Rituximab

MCS + IS (n = 27)
2.0 (2.0, 2.0)
16/24 (66.7)
8/24 (33.3)
1/27 (3.7)
4/27 (14.8)
22/27 (81.5)
11/27 (40.7)
5/27 (18.5)
4/27 (14.8)
2/27 (7.7)
2/27 (7.4)
1/27 (3.7)
1/27 (3.7)
1/27 (3.8)
1/27 (3.7)
11/27 (40.7)
11/26 (42.3)
2/26 (7.4)
6/26 (23.1)
5/26 (19.2)
1/26 (3.8)

All values are reported as n (%) or median (IQR). 2 Immunosuppressants total to >100% as some patients had
more than one agent in regimen. Abbreviations—MCS: mechanical circulatory support, IS: immunosuppression,
VAD: ventricular assist device, IV: intravenous.
1
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3.2. Complications and Outcomes
Complications and outcomes of MCS and immunotherapy are detailed in Table 4. At least
one infectious adverse event was reported in 50.0% (6/12) of cases, three of which were LVAD
infections; 18.2% (2/11) of the patients on maintenance immunosuppression were discontinued from
immunosuppressive therapy due to LVAD infection. Five patients received devices for management of
persistent arrhythmias, including a dual chamber pacemaker in 9.3% (4/43) of patients and implantable
cardioverter defibrillator in one patient (5%, 1/21). Recurrence of GCM after OHT was reported in 8.3%
(2/24) of transplanted cases.
Table 4. Complications and outcomes of patients with GCM treated with MCS alone or in combination
with immunosuppression.
Complications and Outcomes 1
Complications
At least one infectious adverse event
Recurrent GCM
Recurrent GCM after OHT
New dual-chamber pacemaker placed
Renal failure
Severe hemorrhage
Outcomes
Transplant
Time from diagnosis to transplant (days)
Overall mortality at the end of follow-up
30-day mortality
One-year survival
Duration of follow up (months)

MCS alone (n = 16)

MCS + IS (n = 27)

Total (n = 43)

p-Value

1/2 (50.0)
2/16 (12.5)
0/16 (0.0)
1/16 (6.3)
1/16 (6.3)
1/1 (100.0)

5/10 (50.0)
3/27 (11.1)
2/27 (7.4)
3/27 (1.1)
1/19 (5.3)
1/3 (33.3)

6/12 (50.0)
5/43(11.6)
2/43 (4.7)
4/43 (9.3)
2/35 (5.7)
2/4 (50.0)

1.00
1.00
0.71
0.34
0.90
1.00

7/15 (46.7)
175 (123, 270)
11/16 (68.8)
8/16 (50.0)
5/16 (31.2)
1.8 (1.0, 14.0)

17/26 (65.38)
70 (48, 247)
11/27 (40.7)
5/27 (18.5)
16/22 (72.7)
24.0 (3.5, 36.2)

24/41 (58.5)
104 (58, 255)
22/43 (51.2)
13/43 (30.2)
21/38 (55.3)
11.5 (1.0, 34.5)

0.24
0.35
0.14
0.07
0.03
0.06

1

All values are reported as n (%) or median (IQR). Abbreviations—MCS: mechanical circulatory support,
IS: immunosuppression, GCM: giant cell myocarditis, OHT: orthotopic heart transplantation, LVAD: left ventricular
assist device.

One patient in the MCS alone subgroup was successfully weaned of LVAD support on day 222.
No other patients achieved a recovery on MCS as these patients were either transplanted or lost to
follow-up. Two patients (2/43, 4.7%) remained on MCS at the end of the follow-up. There were
no deaths in the bridge to recovery group. 58.5% (24/41) underwent OHT within a median time of
46 (18–201) days from initiation of MCS. A median transplant-free survival of 104 (58–255) days or
3.5 months from diagnosis to transplant was found, with similar values in both groups. No significant
difference in 30-day mortality, combined 30.2% (13/43), or overall mortality at the end of follow-up,
combined 51.2% (22/43), was detected between the two groups. Patients receiving MCS + IS had a
significantly greater 1-year survival (72.7% (16/22) vs. 31.2% (5/16), p = 0.03) compared to patients on
MCS alone. Kaplan–Meier survival analysis stratified by immunosuppression (Figure 2) and mode
of MCS (Figure 3), is shown. Patients with LVADs and patients with BiVADs had similar survival
on Kaplan–Meier analysis (p = 0.36). Table 5 illustrates how immunosuppression status and use of
temporary MCS before durable MCS relate to mortality, by summarizing the results of univariable and
multivariable analysis. Neither immunosuppression nor initial use of temporary MCS were found
to be significantly associated with mortality on multivariable analysis. However, the hazard ratio
of immunosuppression was significantly low (p = 0.049) in univariable analysis and approaching
significance (p = 0.078) in multivariable analysis. Regarding the timing of initiation of immunotherapy,
immunosuppressive treatment started prior to MCS (IS pre-MCS) initiation was associated with
significantly better survival than MCS alone (p = 0.006). We found no difference in survival between
the IS post-MCS and MCS only subgroups and the IS post-MCS and IS pre-MCS subgroups.

support, IABP,
VA-ECMO:
extracorporeal
membrane
oxygenation,
IABP:
*circulatory
Includes VA-ECMO,
Impella,venoarterial
and temporary
VAD, compared
to use of durable
MCS alone.
intra-aortic
balloon
pump,
VAD:
ventricular
assist
device.
Abbreviations—HR: hazard ratio, CI: confidence interval, tMCS: temporary MCS, MCS: mechanical
circulatory support, VA-ECMO: venoarterial extracorporeal membrane oxygenation, IABP:
intra-aortic balloon pump, VAD: ventricular assist device.
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Figure 2. Survival probability of patients with giant cell myocarditis treated with
immunosuppression (IS) before or after mechanical circulatory support (MCS).
Figure 2. Survival probability of patients with giant cell myocarditis treated with immunosuppression
Figure
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with giant cell myocarditis treated with
(IS) before
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circulatory
support (MCS).
immunosuppression (IS) before or after mechanical circulatory support (MCS).

Figure 3. Survival probability of patients with giant cell myocarditis by left ventricular support (LVAD)
Figure
Survival probability
of patients with giant cell myocarditis by left ventricular support
alone
or 3.
biventricular
(BiVAD) support.
(LVAD) alone or biventricular (BiVAD) support.
Table 5. Univariable and multivariable analysis for overall mortality.
Figure 3. Survival probability of patients with giant cell myocarditis by left ventricular support
(LVAD) alone or biventricular (BiVAD) support.Univariable
Multivariable
Variables
Immunosuppression used
tMCS * used before durable MCS

HR (95% CI)
0.42 (0.18–0.99)
0.58 (0.23–1.45)

p-Value
0.049
0.246

HR (95% CI)
0.45 (0.19–1.10)
0.68 (0.27–1.75)

p-Value
0.078
0.429

* Includes VA-ECMO, IABP, Impella, and temporary VAD, compared to use of durable MCS alone.
Abbreviations—HR: hazard ratio, CI: confidence interval, tMCS: temporary MCS, MCS: mechanical circulatory
support, VA-ECMO: venoarterial extracorporeal membrane oxygenation, IABP: intra-aortic balloon pump,
VAD: ventricular assist device.

4. Discussion
4.1. Discussion of Clinical Significance
This study adds to the available literature on the use of MCS for GCM by describing the relative
rates of recovery, transplant, and infection in a cohort of patients receiving contemporary modalities
of mechanical support and immunosuppression. Our study highlights the effectiveness of timely
immunosuppression in prolonging survival in this sick population.

J. Clin. Med. 2020, 9, 3905

8 of 11

Currently, treatment options for GCM include immunosuppression or, in severe cases, OHT,
although patients often die awaiting transplant. Even after OHT, spontaneous recurrence of disease
may occur, first noted [1] by Kong et al. [11] and then Gries et al. [12]. While Gries et al. [12]. recommend
a more cautious transplant evaluation, Kong et al. [11] and Cooper et al. [13] recommend transplant and
triple-immunosuppression. The effectiveness of immunosuppression has been previously demonstrated
in a 1997 study which found immunosuppression increased median transplant-free survival in patients
with GCM from three to 12.3 months [13] after diagnosis. More recently, Maleszewski et al. [14]
reported the possibility of surviving over 19 years [14] on contemporary immunosuppression alone
without the need for transplant. When detected early, typically in young patients who undergo further
testing after discovery of an unexplained distal AV block, immunotherapy achieves a modest clinical
remission in two thirds of patients [6]. Patients with fulminant GCM experience different outcomes
from those with a milder progression of disease [15]. These patients with rapidly progressive heart
failure likely require the institution of MCS to mitigate the effects of GCM on hemodynamic stability
and end-organ function which may not be sufficiently treated by immunosuppression alone [14].
There are a variety of temporary and durable options for MCS in the management of GCM. Of the
temporary options, VA ECMO has been considered favorably [16] in the initial management of patients
with GCM presenting in cardiogenic shock given its ability to provide temporary stabilization until a
diagnosis is made or the need for durable MCS is determined [17]. With VA ECMO support, there is a
need to unload the ventricle with venting or Impella, which has been shown to have disease-modifying
effects [18,19]. CF-LVADs and BiVADs, through improved quality of life, organ performance,
and hemodynamic stability, have extended the life expectancy of patients with end-stage heart
failure [20,21]. Since patients with GCM have a similar post-transplant survival [22] as patients with
all other heart diseases treated with OHT, bridging patients to transplant is crucial and valuable.
Another reported benefit [16] of MCS is its ability to support the ventricle if it becomes irritated after
EMB, the gold-standard [23] for GCM diagnosis. Early biopsy is critical for patients with suspected
GCM, given that rates of transplant and death have been reported [17] as high as 80% to 100% in
patients who do not receive a biopsy. Patients often require repetitive biopsies when the results
are inconclusive or disease recurrence is suspected [24]. MCS can relieve the stress on the ventricle
following EMB, thus preventing exacerbation of pre-existing arrhythmias [25], a known complication
of EMB [26].
Regarding durable MCS options for GCM, biventricular support is recommended given that
the inflammation of GCM can affect both ventricles [27]. However, we did not detect a difference in
survival between patients on CF-LVADs and those on BiVADs. The majority of patients in our study
received a BiVAD, and the decision to use a CF-LVAD in place of BiVAD in 23.3% (10/43) of patients
was not specified. In three of the patients receiving a CF-LVAD, GCM was diagnosed after device
implantation. In these cases, patients likely presented in a severe condition requiring rapid MCS
before a diagnosis could be made. Additionally, BiVADs are used in patients with a concomitant right
ventricular failure who are unlikely to recover. Patients who were predicted to recover likely received
a bridge-to-recovery LVAD instead of a BiVAD. One patient in our study was supported with TAH.
Although there are limited data on the use of TAH in GCM, one study reports [20] a good prognosis
and recommends its use as a bridge to transplant when a longer time to transplant is expected, such as
in patients with blood types O and A.
When examining the patient subgroups with improved survival, treatment involving both
immunosuppression and MCS (MCS + IS) was associated with better overall survival compared to
treatment with MCS alone. Immunosuppression may reduce the severity of heart failure in these
patients by preventing further autoimmune destruction of the myocardium. These patients may
also have had better survival because they presented in less severe heart failure. At the time of
initial presentation, we observed that patients who received MCS + IS had a significantly higher
LVEF at presentation compared to patients who received MCS alone (28% (20–30) vs. 17% (13–20),
p = 0.03). Previous studies [17] have also reported that patients with a milder presentation or insidious
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course have less severe outcomes than those who present in acute cardiac compromise. Specifically in
this study, the administration of immunosuppression prior to MCS implantation (IS pre-MCS) was
associated with increased survival. However, given the limitations of these data, it is not clear why
IS pre-MCS is effective. The ability to initiate IS prior to MCS may indicate a more indolent disease
course, allowing more time for IS to be instituted when compared to acutely severe presentations
requiring rapid MCS intervention. Since we observed that patients with a higher systolic function at
presentation tended to receive IS more frequently and survived longer, future studies investigating
LVEF as a factor in determining candidates eligible for early immunosuppression may be valuable.
Our study introduces a key element in clinical management of patients with GCM: timing of
immunosuppression. Early biopsy and immunosuppression have been recommended [16], but there
are few data describing its exact impact on survival. To our knowledge, our study is the first to provide
evidence that early immunosuppression (defined as the initiation of IS prior to MCS) is associated with
better long-term survival. Immunosuppression likely reduces the severity of heart failure by curbing
the autoimmune destruction of the myocardium. Patients receiving IS pre-MCS may also have had a
milder disease progression, allowing more time for institution of IS prior to MCS.
4.2. Limitations and Future Directions
Since we extracted data from articles with different purposes, we were unable to collect all
variables for each patient. Those receiving MCS alone could be sicker than patients receiving MCS
+ IS, as suggested by the difference in LVEF at presentation between these two groups. However,
given the lack of granular data, we could not further characterize the severity of illness or control
for confounding effects. Additionally, our study included all immunosuppressants under a broad
“immunosuppression” category, so we are not able to provide more detail on the relative effectiveness of
specific drugs. During the 10-year period encompassed by this study, immunosuppression has evolved.
Triple immunosuppression [28] with corticosteroids, cyclosporine, and azathioprine or mycophenolate
mofetil has been widely used in GCM, along with antithymocyte globulin in the modern era. Clinical
outcomes may vary by regimen.
It is important to consider infection in patients who are immunosuppressed. One study
reported that 75% of patients on long-term immunosuppression for GCM experienced at least
one infection-related readmission [29]. Only 12 cases in our study mentioned infection. Infection was
likely underreported, and we felt it was inappropriate to assume the absence of infection when it was
not explicitly stated. Future investigations into infectious complications may be valuable in guiding
clinical management.
5. Conclusions
Most patients with GCM who require MCS need BiVAD support. Survival in patients with GCM
requiring MCS may be improved when immunosuppression is initiated before MCS implantation.
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